1. DSpace at Nirma University
  2. 04. Institute of Pharmacy
  3. B. Pharm Project Reports
Please use this identifier to cite or link to this item: http://10.1.7.192:80/jspui/handle/123456789/9678
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBhatt, Jeel M.-
dc.date.accessioned2021-01-29T10:50:44Z-
dc.date.available2021-01-29T10:50:44Z-
dc.date.issued2020-05-
dc.identifier.urihttp://10.1.7.192:80/jspui/handle/123456789/9678-
dc.descriptionGuided by Dr.Mohit Shahen_US
dc.description.abstractBrest cancer is worldwide most common originates of cancer death in women.Triple negative is called beoriginates this type of cancer has negative action of estrogen receptor, progesterone receptor and HER2 receptor. In modern era, one of the advance treatment of TNBC is based on immunananotherapy by working on immune checkpoint receptors and many other ways, treatment using nanotechnology and triple hit approach. Aim of this review is to introduce some recent advances in treatment of triple negative cancer of the breast, their mode of actions and future prospective in cancer drugs.en_US
dc.publisherInstitute of Pharmacy, Nirma University, A'baden_US
dc.relation.ispartofseriesPPR00958;-
dc.subjectPPR00958en_US
dc.subjectB. Pharm Project Reporten_US
dc.subjectPharmaceuticsen_US
dc.subjectCanceren_US
dc.subjectBreast Canceren_US
dc.subjectImmunananotherapyen_US
dc.subjectImmunocheckpoint receptorsen_US
dc.subjectNano technologyen_US
dc.titleRecent Advances In Treatment of Triple Negative Breast Canceren_US
dc.typeProject Reporten_US
Appears in Collections:B. Pharm Project Reports

Files in This Item:
File Description SizeFormat 
PPR00958.pdfPPR009582.14 MBAdobe PDFThumbnail
View/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.